

# Steven G Deeks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656291/publications.pdf>

Version: 2024-02-01

592  
papers

61,929  
citations

588

125  
h-index

1347

223  
g-index

643  
all docs

643  
docs citations

643  
times ranked

35981  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 95-104.	5.8	31
2	Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 127-130.	1.1	3
3	Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time. <i>Journal of Infectious Diseases</i> , 2022, 225, 1168-1178.	4.0	9
4	Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. <i>Clinical Infectious Diseases</i> , 2022, 74, 865-870.	5.8	30
5	Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 1721-1730.	4.0	7
6	Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 221-226.	3.7	53
7	Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. <i>Frontiers in Immunology</i> , 2022, 13, 803417.	4.8	12
8	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	12.4	50
9	IFN- $\gamma$ blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. <i>JCI Insight</i> , 2022, 7, .	5.0	6
10	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	52
11	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e916-e919.	5.8	42
12	Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. <i>Nature Immunology</i> , 2022, 23, 360-370.	14.5	34
13	Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes. <i>Journal of Virology</i> , 2022, 96, jvi0201121.	3.4	18
14	Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 510-517.	1.1	4
15	Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	13
16	SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. <i>Annals of Neurology</i> , 2022, 91, 772-781.	5.3	63
17	Findings From Mayo Clinic's Post-COVID Clinic: PASC Phenotypes Vary by Sex and Degree of IL-6 Elevation. <i>Mayo Clinic Proceedings</i> , 2022, 97, 430-432.	3.0	8
18	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. <i>Nature Communications</i> , 2022, 13, 1219.	12.8	20

#	ARTICLE	IF	CITATIONS
19	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infectionâ€”study protocol for a two-stage randomised phase II trial. <i>Trials</i> , 2022, 23, 263.	1.6	6
20	Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	5.0	24
21	Early clues regarding the pathogenesis of long-COVID. <i>Trends in Immunology</i> , 2022, 43, 268-270.	6.8	79
22	Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. <i>BMC Medical Ethics</i> , 2022, 23, 39.	2.4	2
23	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.9	56
24	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. <i>International Journal of Behavioral Medicine</i> , 2022, 29, 610-623.	1.7	9
25	Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV. <i>EBioMedicine</i> , 2022, 80, 104037.	6.1	13
26	CE-541-04 CARDIAC ARRHYTHMIAS IN POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION ASSESSED BY AMBULATORY RHYTHM MONITORING. <i>Heart Rhythm</i> , 2022, 19, S54-S55.	0.7	0
27	Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. <i>EBioMedicine</i> , 2022, 80, 104072.	6.1	9
28	Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- $\kappa$ B signaling. <i>JCI Insight</i> , 2022, 7, .	5.0	23
29	Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	41
30	Magnitude and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, S193-S204.	5.8	9
31	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. <i>Journal of Infectious Diseases</i> , 2021, 224, 1209-1218.	4.0	18
32	Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. <i>American Journal of Transplantation</i> , 2021, 21, 1765-1779.	4.7	14
33	NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 11-18.	2.1	11
34	Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 1621-1630.	4.0	20
35	Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach. <i>Clinical Infectious Diseases</i> , 2021, 72, 1843-1849.	5.8	15
36	The case for an HIV cure and how to get there. <i>Lancet HIV</i> , the, 2021, 8, e51-e58.	4.7	46

#	ARTICLE	IF	CITATIONS
37	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1839-1848.	4.0	176
38	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. <i>Cells</i> , 2021, 10, 386.	4.1	125
39	Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. <i>Journal of NeuroVirology</i> , 2021, 27, 191-195.	2.1	95
40	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. <i>JCI Insight</i> , 2021, 6, .	5.0	43
41	Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	103
42	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	6.1	24
43	Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. <i>Journal of Infectious Diseases</i> , 2021, 224, 1593-1598.	4.0	14
44	Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity <i>Ex Vivo</i> and <i>In Vivo</i>. <i>Journal of Virology</i> , 2021, 95, .	3.4	13
45	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	5.8	34
46	CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART. <i>Viruses</i> , 2021, 13, 799.	3.3	6
47	Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. <i>Cell Reports</i> , 2021, 35, 109038.	6.4	15
48	A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. <i>Cell Reports Medicine</i> , 2021, 2, 100243.	6.5	44
49	Brief Report: Lower Socioeconomic Status Associates With Greater Systemic and Arterial Inflammation in HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 706-710.	2.1	1
50	The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
51	Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 489-501.	1.1	4
52	Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab393.	0.9	3
53	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	10.3	117
54	SARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, e232-e233.	2.1	2

#	ARTICLE	IF	CITATIONS
55	HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. <i>Frontiers in Immunology</i> , 2021, 12, 740395.	4.8	6
56	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. <i>Cell Reports</i> , 2021, 36, 109518.	6.4	142
57	HIV-1 Genomes Are Enriched in Memory CD4 <sup>+</sup> T-Cells with Short Half-Lives. <i>MBio</i> , 2021, 12, e0244721.	4.1	11
58	Functional impairment of HIV-specific CD8 <sup>+</sup> T cells precedes aborted spontaneous control of viremia. <i>Immunity</i> , 2021, 54, 2372-2384.e7.	14.3	20
59	Multi-stakeholder consensus on a target product profile for an HIV cure. <i>Lancet HIV</i> , 2021, 8, e42-e50.	4.7	38
60	Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. <i>Journal of Leukocyte Biology</i> , 2021, 110, 21-26.	3.3	82
61	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. <i>PLoS Pathogens</i> , 2021, 17, e1009214.	4.7	25
62	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa531.	0.9	9
63	Losartan to reduce inflammation and fibrosis endpoints in HIV disease. <i>Aids</i> , 2021, 35, 575-583.	2.2	11
64	Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States. <i>AIDS Research and Therapy</i> , 2021, 18, 75.	1.7	6
65	Effect of HIV-1 Infection on Angiopoietin 1 and 2 Levels and Measures of Microvascular and Macrovascular Endothelial Dysfunction. <i>Journal of the American Heart Association</i> , 2021, 10, e021397.	3.7	5
66	Identification and Characterization of Antigen-Specific CD8 <sup>+</sup> T Cells Using Surface-Trapped TNF- $\alpha$ and Single-Cell Sequencing. <i>Journal of Immunology</i> , 2021, , j12100535.	0.8	2
67	SARS-CoV-2 booster vaccination for participants in an HIV cure-related clinical trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, e30.	2.1	1
68	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021, 27, 2085-2098.	30.7	146
69	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. <i>Science Translational Medicine</i> , 2021, 13, eabl4097.	12.4	52
70	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 70, 1176-1185.	5.8	27
71	Circulating CD30 <sup>+</sup> CD4 <sup>+</sup> T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2020, 221, 1146-1155.	4.0	11
72	High levels of genetically intact HIV in HLA-DR <sup>+</sup> memory T cells indicates their value for reservoir studies. <i>Aids</i> , 2020, 34, 659-668.	2.2	32

#	ARTICLE	IF	CITATIONS
73	Plasma tissue factor and immune activation are associated with carotid intima-media thickness progression in treated HIV infection. <i>Aids</i> , 2020, 34, 519-528.	2.2	4
74	Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 744-755.	4.0	39
75	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. <i>Journal of Virus Eradication</i> , 2020, 6, 19-26.	0.5	6
76	A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. <i>Journal of Virus Eradication</i> , 2020, 6, 34-37.	0.5	26
77	Mining for humoral correlates of HIV control and latent reservoir size. <i>PLoS Pathogens</i> , 2020, 16, e1008868.	4.7	19
78	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18692-18700.	7.1	67
79	A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 73, e2845-e2846.	5.8	6
80	HLA tapasin independence: broader peptide repertoire and HIV control. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28232-28238.	7.1	51
81	Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. <i>Aids</i> , 2020, 34, 2013-2024.	2.2	14
82	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 <sup>+</sup> and Gut CD4 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2020, 95, .	3.4	4
83	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. <i>Nature</i> , 2020, 585, 261-267.	27.8	245
84	The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 973-981.	1.1	11
85	Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	10
86	Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection. <i>JAMA Network Open</i> , 2020, 3, e2018099.	5.9	20
87	Delayed Expression of PD-1 and TIGIT on HIV-Specific CD8 T Cells in Untreated HLA-B*57:01 Individuals Followed from Early Infection. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
88	CXCR4-Using HIV Strains Predominate in Naïve and Central Memory CD4 <sup>+</sup> T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained. <i>Journal of Virology</i> , 2020, 94, .	3.4	18
89	“Rinse and Replace”: Boosting T Cell Turnover To Reduce HIV-1 Reservoirs. <i>Trends in Immunology</i> , 2020, 41, 466-480.	6.8	26
90	Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	75

#	ARTICLE	IF	CITATIONS
91	FOXO1 promotes HIV latency by suppressing ER stress in T cells. <i>Nature Microbiology</i> , 2020, 5, 1144-1157.	13.3	18
92	Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1837-1842.	4.0	3
93	Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1604-1610.	3.0	8
94	Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes. <i>Nature Immunology</i> , 2020, 21, 578-587.	14.5	63
95	Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 530-537.	2.1	17
96	HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. <i>Nature Immunology</i> , 2020, 21, 274-286.	14.5	60
97	Different human resting memory CD4 <sup>+</sup> T cell subsets show similar low inducibility of latent HIV-1 proviruses. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	73
98	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. <i>PLoS ONE</i> , 2020, 15, e0232636.	2.5	3
99	Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. <i>PLoS Pathogens</i> , 2020, 16, e1008450.	4.7	34
100	The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. <i>Cell Host and Microbe</i> , 2020, 27, 519-530.	11.0	173
101	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. <i>Journal of Virology</i> , 2020, 94, .	3.4	20
102	Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 519.	4.8	7
103	Differential decay of intact and defective proviral DNA in HIV-1â€“infected individuals on suppressive antiretroviral therapy. <i>JCI Insight</i> , 2020, 5, .	5.0	140
104	Longitudinal study reveals HIV-1â€“infected CD4+ T cell dynamics during long-term antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 3543-3559.	8.2	69
105	Filgotinib suppresses HIV-1â€“driven gene transcription by inhibiting HIV-1 splicing and T cell activation. <i>Journal of Clinical Investigation</i> , 2020, 130, 4969-4984.	8.2	26
106	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. <i>Pathogens and Immunity</i> , 2020, 5, 143.	3.1	42
107	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. <i>ELife</i> , 2020, 9, .	6.0	63
108	The immune response fails to control HIV early in initial virus spread. <i>Journal of Clinical Investigation</i> , 2020, 130, 2803-2805.	8.2	1



#	ARTICLE	IF	CITATIONS
109	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 2020, 6, 19-26.	0.5	3
110	A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. Journal of Virus Eradication, 2020, 6, 34-37.	0.5	17
111	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
112	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
113	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
114	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
115	Title is missing!. , 2020, 16, e1008450.		0
116	Title is missing!. , 2020, 16, e1008450.		0
117	Title is missing!. , 2020, 16, e1008450.		0
118	Title is missing!. , 2020, 16, e1008450.		0
119	Title is missing!. , 2020, 16, e1008450.		0
120	Title is missing!. , 2020, 16, e1008450.		0
121	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 692-702.	4.7	29
122	Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. Journal of Infectious Diseases, 2019, 220, S1-S4.	4.0	21
123	How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?. Journal of Infectious Diseases, 2019, 220, S24-S26.	4.0	14
124	Effector memory differentiation increases detection of replication-competent HIV-1 in resting CD4+ T cells from virally suppressed individuals. PLoS Pathogens, 2019, 15, e1008074.	4.7	41
125	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 2214.	3.5	38
126	Attacking Latent HIV with convertible CAR-T Cells, a Highly Adaptable Killing Platform. Cell, 2019, 179, 880-894.e10.	28.9	95



#	ARTICLE	IF	CITATIONS
127	Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members. ELife, 2019, 8, .	6.0	17
128	HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. Molecular Therapy - Methods and Clinical Development, 2019, 15, 9-17.	4.1	19
129	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature, 2019, 566, 120-125.	27.8	471
130	Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. Journal of Virology, 2019, 93, .	3.4	41
131	Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 89-93.	2.1	41
132	Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. Frontiers in Immunology, 2019, 10, 1021.	4.8	8
133	CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. Nature Immunology, 2019, 20, 824-834.	14.5	87
134	HIV – cure – A shot in the arm?. EBioMedicine, 2019, 42, 3-5.	6.1	11
135	Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV-Infected Adults. Journal of the American Heart Association, 2019, 8, e011037.	3.7	15
136	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV, the, 2019, 6, e240-e249.	4.7	46
137	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials – report of a consensus meeting. Lancet HIV, the, 2019, 6, e259-e268.	4.7	139
138	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Computational Biology, 2019, 15, e1006849.	3.2	22
139	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. Statistics in Medicine, 2019, 38, 2428-2446.	1.6	13
140	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nature Communications, 2019, 10, 814.	12.8	149
141	Statistical analysis of single-copy assays when some observations are zero. Journal of Virus Eradication, 2019, 5, 167-173.	0.5	5
142	Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25891-25899.	7.1	78
143	Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8 <sup>+</sup> T cells. Science Translational Medicine, 2019, 11, .	12.4	81
144	Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4 <sup>+</sup> T Cells. Journal of Virology, 2019, 93, .	3.4	72

#	ARTICLE	IF	CITATIONS
145	HIV elite control is associated with reduced TRAILshort expression. <i>Aids</i> , 2019, 33, 1757-1763.	2.2	5
146	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 211-219.	2.1	14
147	Why and where an HIV cure is needed and how it might be achieved. <i>Nature</i> , 2019, 576, 397-405.	27.8	90
148	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. <i>Clinical Infectious Diseases</i> , 2019, 68, 795-802.	5.8	13
149	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. <i>Clinical Infectious Diseases</i> , 2019, 68, 1877-1886.	5.8	42
150	Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency. <i>PLoS Pathogens</i> , 2019, 15, e1007498.	4.7	46
151	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	4.0	73
152	HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 4629-4642.	8.2	84
153	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. <i>Pathogens and Immunity</i> , 2019, 4, 147.	3.1	15
154	Statistical analysis of single-copy assays when some observations are zero. <i>Journal of Virus Eradication</i> , 2019, 5, 167-173.	0.5	5
155	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. <i>Journal of Infectious Diseases</i> , 2018, 217, 1024-1032.	4.0	29
156	Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. <i>Journal of Immunology</i> , 2018, 200, 1876-1888.	0.8	28
157	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2018, 218, 239-248.	4.0	29
158	Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells. <i>Science</i> , 2018, 359, 86-90.	12.6	135
159	Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection. <i>Mucosal Immunology</i> , 2018, 11, 909-920.	6.0	38
160	Unique Circulating MicroRNA Profiles in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 644-650.	2.1	16
161	Maximising the global health impact of future HIV cure-related interventions through advance planning. <i>Journal of Virus Eradication</i> , 2018, 4, 182-185.	0.5	3
162	Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. <i>PLoS Pathogens</i> , 2018, 14, e1007357.	4.7	76

#	ARTICLE	IF	CITATIONS
163	IL-1 $\beta$ Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. Journal of the American College of Cardiology, 2018, 72, 2809-2811.	2.8	59
164	Ethical issues in HIV remission trials. Current Opinion in HIV and AIDS, 2018, 13, 422-427.	3.8	22
165	Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. Aids, 2018, 32, 2119-2128.	2.2	28
166	HIV control: Is getting there the same as staying there?. PLoS Pathogens, 2018, 14, e1007222.	4.7	65
167	Short Communication: Dried Blood Spots Stored at Room Temperature Should Not Be Used for HIV Incidence Testing. AIDS Research and Human Retroviruses, 2018, 34, 1013-1016.	1.1	4
168	Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Advances, 2018, 2, 3479-3482.	5.2	14
169	A randomized, controlled trial of mindfulness-based stress reduction in HIV infection. Brain, Behavior, and Immunity, 2018, 73, 331-339.	4.1	32
170	Identification and characterization of HIV-specific resident memory CD8 <sup>+</sup> T cells in human lymphoid tissue. Science Immunology, 2018, 3, .	11.9	116
171	Limited immune surveillance in lymphoid tissue by cytolytic CD4 <sup>+</sup> T cells during health and HIV disease. PLoS Pathogens, 2018, 14, e1006973.	4.7	30
172	Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4 <sup>+</sup> T cells. ELife, 2018, 7, .	6.0	126
173	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7795-E7804.	7.1	121
174	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Annals of Oncology, 2018, 29, 2141-2142.	1.2	47
175	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. Journal of Infectious Diseases, 2018, 218, 1954-1963.	4.0	130
176	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Journal of Infectious Diseases, 2018, 218, 1394-1403.	4.0	36
177	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathogens, 2018, 14, e1006806.	4.7	12
178	The role of CD32 during HIV-1 infection. Nature, 2018, 561, E17-E19.	27.8	43
179	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. Journal of Clinical Investigation, 2018, 128, 1903-1912.	8.2	52
180	Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. PLoS ONE, 2018, 13, e0191613.	2.5	76

#	ARTICLE	IF	CITATIONS
181	Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathogens, 2018, 14, e1006856.	4.7	70
182	Maximising the global health impact of future HIV cure-related interventions through advance planning. Journal of Virus Eradication, 2018, 4, 182-185.	0.5	2
183	Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication <i>In Vitro</i> and Modulate HIV Restriction Factor Expression. Journal of Virology, 2017, 91, .	3.4	33
184	Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Scientific Reports, 2017, 7, 40354.	3.3	65
185	Mucosal Microbes Mitigate Maladies. Immunity, 2017, 46, 1-3.	14.3	7
186	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV, the, 2017, 4, e251-e259.	4.7	10
187	A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads. Virology, 2017, 507, 135-139.	2.4	43
188	High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. EBioMedicine, 2017, 20, 217-229.	6.1	50
189	HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication. Journal of Infectious Diseases, 2017, 216, 72-81.	4.0	38
190	Signature of the Sleeper Cell: A Biomarker of HIV Latency Revealed. Trends in Immunology, 2017, 38, 457-458.	6.8	10
191	Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. Journal of Virology, 2017, 91, .	3.4	32
192	SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. Cell Host and Microbe, 2017, 21, 569-579.e6.	11.0	78
193	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 911-919.	4.0	95
194	Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57:01 Is Only Observed in Viremic Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e90-e92.	2.1	12
195	Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies. Journal of Infectious Diseases, 2017, 215, S134-S141.	4.0	39
196	Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. Scientific Reports, 2017, 7, 3818.	3.3	10
197	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Research and Human Retroviruses, 2017, 33, 658-667.	1.1	22
198	Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection. JAMA Cardiology, 2017, 2, 163.	6.1	50

#	ARTICLE	IF	CITATIONS
199	Psoriasis risk SNPs and their association with HIV-1 control. <i>Human Immunology</i> , 2017, 78, 179-184.	2.4	10
200	Defining total-body AIDS-virus burden with implications for curative strategies. <i>Nature Medicine</i> , 2017, 23, 1271-1276.	30.7	322
201	An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, S-31-S-39.	1.1	23
202	Identification of Genetically Intact HIV-1 Proviruses in Specific CD4 + T Cells from Effectively Treated Participants. <i>Cell Reports</i> , 2017, 21, 813-822.	6.4	304
203	Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	39
204	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	14
205	Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	21
206	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	5.8	67
207	High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 234-245.	1.1	3
208	Predominance of weakly cytotoxic, T-bet <sup>Low</sup> Eomes <sup>Neg</sup> CD8 <sup>+</sup> T-cells in human gastrointestinal mucosa: implications for HIV infection. <i>Mucosal Immunology</i> , 2017, 10, 1008-1020.	6.0	28
209	Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. <i>PLoS ONE</i> , 2017, 12, e0172283.	2.5	17
210	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. <i>PLoS ONE</i> , 2017, 12, e0183357.	2.5	34
211	Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. <i>Retrovirology</i> , 2017, 14, 41.	2.0	22
212	T-bet <sup>+</sup> B cells are induced by human viral infections and dominate the HIV gp140 response. <i>JCI Insight</i> , 2017, 2, .	5.0	164
213	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	8.4	186
214	The end of HIV: Still a very long way to go, but progress continues. <i>PLoS Medicine</i> , 2017, 14, e1002466.	8.4	14
215	Trans-Activation Response Element RNA is Detectable in the Plasma of a Subset of Aviremic HIV-1 <sup>+</sup> Infected Patients. <i>Acta Chimica Slovenica</i> , 2017, 64, 530-536.	0.6	11
216	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. <i>Pathogens and Immunity</i> , 2017, 2, 310.	3.1	10

#	ARTICLE	IF	CITATIONS
217	The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?. Journal of Clinical Investigation, 2016, 127, 103-105.	8.2	29
218	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. PLoS ONE, 2016, 11, e0155100.	2.5	150
219	Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection. PLoS ONE, 2016, 11, e0146355.	2.5	14
220	p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS ONE, 2016, 11, e0166759.	2.5	10
221	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 2016, 12, e1005381.	4.7	37
222	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
223	Persistence of integrated HIV DNA in CXCR3+CCR6+ memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. Aids, 2016, 30, 1511-1520.	2.2	68
224	Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 206-213.	2.1	95
225	Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. Aids, 2016, 30, 2065-2074.	2.2	79
226	Reverse geroscience: how does exposure to early diseases accelerate the age-related decline in health?. Annals of the New York Academy of Sciences, 2016, 1386, 30-44.	3.8	24
227	Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV. Journal of the American Heart Association, 2016, 5, .	3.7	50
228	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 214-221.	2.1	22
229	T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment. Journal of Infectious Diseases, 2016, 214, 216-225.	4.0	97
230	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Research and Human Retroviruses, 2016, 32, 791-800.	1.1	11
231	HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". Journal of the American Heart Association, 2016, 5, .	3.7	36
232	Defective proviruses rapidly accumulate during acute HIV-1 infection. Nature Medicine, 2016, 22, 1043-1049.	30.7	605
233	The Benefits of Early Antiretroviral Therapy for HIV Infection: How Early is Early Enough?. EBioMedicine, 2016, 11, 7-8.	6.1	10
234	Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell, 2016, 166, 1004-1015.	28.9	156



#	ARTICLE	IF	CITATIONS
235	New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. <i>Retrovirology</i> , 2016, 13, 59.	2.0	90
236	Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw189.	0.9	72
237	Persistent HIV-1 replication during antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 417-423.	3.8	133
238	Immunologic profiles distinguish aviremic HIV-infected adults. <i>Aids</i> , 2016, 30, 1553-1562.	2.2	22
239	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79.	4.0	13
240	Post-Treatment Controllers: Role in HIV “Cure” Research. <i>Current HIV/AIDS Reports</i> , 2016, 13, 1-9.	3.1	31
241	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
242	HIV reservoirs: what, where and how to target them. <i>Nature Reviews Microbiology</i> , 2016, 14, 55-60.	28.6	259
243	Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals. <i>Aids</i> , 2016, 30, 45-55.	2.2	23
244	Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160192.	2.5	26
245	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. <i>PLoS ONE</i> , 2016, 11, e0160341.	2.5	7
246	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005349.	4.7	271
247	Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. <i>PLoS Pathogens</i> , 2016, 12, e1005677.	4.7	78
248	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. <i>PLoS Pathogens</i> , 2016, 12, e1005761.	4.7	350
249	A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. <i>EBioMedicine</i> , 2015, 2, 874-883.	6.1	242
250	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	30.5	340
251	Geriatric Syndromes in Older HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 161-167.	2.1	192
252	Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 $\Delta 32$ . <i>Aids</i> , 2015, 29, 867-876.	2.2	26



#	ARTICLE	IF	CITATIONS
253	Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects. PLoS ONE, 2015, 10, e0127662.	2.5	1
254	Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. PLoS ONE, 2015, 10, e0130592.	2.5	4
255	CD8 <sup>+</sup> T-Cells Count in Acute Myocardial Infarction in HIV Disease in a Predominantly Male Cohort. BioMed Research International, 2015, 2015, 1-5.	1.9	17
256	The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. Journal of Virus Eradication, 2015, 1, 245-249.	0.5	12
257	CD4/CD8 ratio: an emerging biomarker for HIV. Lancet HIV,the, 2015, 2, e76-e77.	4.7	31
258	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV,the, 2015, 2, e520-e529.	4.7	213
259	High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men—San Francisco, California: Table 1.. Journal of Infectious Diseases, 2015, 211, 1757-1760.	4.0	23
260	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature, 2015, 517, 381-385.	27.8	469
261	Lymphoid Fibrosis Occurs in Long-Term Nonprogressors and Persists With Antiretroviral Therapy but May Be Reversible With Curative Interventions. Journal of Infectious Diseases, 2015, 211, 1068-1075.	4.0	49
262	Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8 <sup>+</sup> T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression. Journal of Virology, 2015, 89, 3723-3736.	3.4	71
263	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. Lancet HIV,the, 2015, 2, e82-e91.	4.7	34
264	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. Journal of Infectious Diseases, 2015, 212, 596-607.	4.0	138
265	Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC: Heart Failure, 2015, 3, 591-599.	4.1	65
266	Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell—Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. Journal of Immunology, 2015, 194, 5320-5328.	0.8	29
267	CD4 <sup>+</sup> T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. International Journal of Epidemiology, 2015, 44, 251-263.	1.9	10
268	Gut epithelial barrier and systemic inflammation during chronic HIV infection. Aids, 2015, 29, 43-51.	2.2	156
269	Select host restriction factors are associated with HIV persistence during antiretroviral therapy. Aids, 2015, 29, 411-420.	2.2	54
270	Virome analysis of antiretroviral-treated HIV patients shows no correlation between T-cell activation and anelloviruses levels. Journal of Clinical Virology, 2015, 72, 106-113.	3.1	26

#	ARTICLE	IF	CITATIONS
271	Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4762-71.	7.1	48
272	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	5.8	142
273	The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.5	7
274	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. <i>PLoS ONE</i> , 2014, 9, e85516.	2.5	34
275	Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging. <i>PLoS ONE</i> , 2014, 9, e89444.	2.5	85
276	Towards an HIV cure. <i>Journal of the International AIDS Society</i> , 2014, 17, 19479.	3.0	8
277	Cutting Edge: An Antibody Recognizing Ancestral Endogenous Virus Glycoproteins Mediates Antibody-Dependent Cellular Cytotoxicity on HIV-1-Infected Cells. <i>Journal of Immunology</i> , 2014, 193, 1544-1548.	0.8	21
278	Cut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 1228-1238.	4.0	395
279	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2014, 210, 1248-1259.	4.0	464
280	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. <i>PLoS Pathogens</i> , 2014, 10, e1004345.	4.7	76
281	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	5.8	65
282	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. <i>PLoS Pathogens</i> , 2014, 10, e1004078.	4.7	495
283	LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. <i>PLoS Genetics</i> , 2014, 10, e1004196.	3.5	83
284	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>PLoS Pathogens</i> , 2014, 10, e1004473.	4.7	437
285	Reply to Karch et al. <i>Journal of Infectious Diseases</i> , 2014, 210, 159-160.	4.0	0
286	The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 210, 383-391.	4.0	101
287	Discordance Between Peripheral and Colonic Markers of Inflammation During Suppressive ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 133-141.	2.1	23
288	A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. <i>Aids</i> , 2014, 28, 439-442.	2.2	62

#	ARTICLE	IF	CITATIONS
289	Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. <i>Aids</i> , 2014, 28, 317-323.	2.2	25
290	HIV Prevention and Treatment Fields Join Forces. <i>EBioMedicine</i> , 2014, 1, 4-5.	6.1	2
291	A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2014, 58, 883-890.	5.8	166
292	Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. <i>Aids</i> , 2014, 28, 1749-1758.	2.2	101
293	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796.	2.2	25
294	A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. <i>Aids</i> , 2014, 28, 1289-1295.	2.2	36
295	A closer look at hepatitis C clearance in HIV controllers. <i>Aids</i> , 2014, 28, 1241-1242.	2.2	3
296	Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. <i>Retrovirology</i> , 2014, 11, 10.	2.0	43
297	Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 1549-1554.	4.0	80
298	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>in Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 763-767.	3.4	29
299	Reduction of HIV Persistence Following Transplantation in HIV-Infected Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 1136-1141.	4.7	57
300	Galectin-9 Is Rapidly Released During Acute HIV-1 Infection and Remains Sustained at High Levels Despite Viral Suppression Even in Elite Controllers. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 654-664.	1.1	78
301	Decreased HIV Type 1 Transcription in CCR5-Δ32 Heterozygotes During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 210, 1838-1843.	4.0	11
302	The CD8 <sup>+</sup> Memory Stem T Cell (T <sub>SCM</sub> ) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection. <i>Journal of Virology</i> , 2014, 88, 13836-13844.	3.4	53
303	Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4 + T cells. <i>Immunology and Cell Biology</i> , 2014, 92, 770-780.	2.3	15
304	Towards a cure for HIV—are we making progress?. <i>Lancet</i> , The, 2014, 384, 209-211.	13.7	25
305	Antiretroviral therapy: stubborn limitations persist. <i>Lancet</i> , The, 2014, 384, 214-216.	13.7	2
306	HIV Antibody Characterization as a Method to Quantify Reservoir Size During Curative Interventions. <i>Journal of Infectious Diseases</i> , 2014, 209, 1613-1617.	4.0	48

#	ARTICLE	IF	CITATIONS
307	Immunologic strategies for HIV-1 remission and eradication. <i>Science</i> , 2014, 345, 169-174.	12.6	193
308	Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 279-286.	5.8	35
309	Low Proportions of CD28 <sup>hi</sup> CD8 <sup>+</sup> T cells Expressing CD57 Can Be Reversed by Early ART Initiation and Predict Mortality in Treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 374-382.	4.0	53
310	Dependence on the CCR5 Coreceptor for Viral Replication Explains the Lack of Rebound of CXCR4-Predicted HIV Variants in the Berlin Patient. <i>Clinical Infectious Diseases</i> , 2014, 59, 596-600.	5.8	35
311	Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4 <sup>+</sup> T cell recovery after the initiation of antiretroviral therapy for HIV disease. <i>AIDS Research and Therapy</i> , 2014, 11, 27.	1.7	2
312	Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. <i>Aids</i> , 2014, 28, 511-519.	2.2	37
313	Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease. <i>PLoS ONE</i> , 2014, 9, e85613.	2.5	41
314	Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs. <i>PLoS ONE</i> , 2014, 9, e92934.	2.5	34
315	CD4 <sup>+</sup> and CD8 <sup>+</sup> T Cell Activation Are Associated with HIV DNA in Resting CD4 <sup>+</sup> T Cells. <i>PLoS ONE</i> , 2014, 9, e110731.	2.5	88
316	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4 <sup>+</sup> T Cell Recovery: A Randomized Crossover Trial. <i>PLoS ONE</i> , 2014, 9, e116306.	2.5	56
317	Biomarker reveals HIV's hidden reservoir. <i>ELife</i> , 2014, 3, e04742.	6.0	5
318	Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. <i>Science Translational Medicine</i> , 2013, 5, 193ra91.	12.4	578
319	Systemic Effects of Inflammation on Health during Chronic HIV Infection. <i>Immunity</i> , 2013, 39, 633-645.	14.3	651
320	Elevated levels of asymmetric dimethylarginine are associated with lower CD4 <sup>+</sup> count and higher viral load in HIV-infected individuals. <i>Atherosclerosis</i> , 2013, 229, 246-252.	0.8	20
321	Antibodies advance the search for a cure. <i>Nature</i> , 2013, 503, 207-208.	27.8	6
322	The end of AIDS: HIV infection as a chronic disease. <i>Lancet</i> , The, 2013, 382, 1525-1533.	13.7	1,428
323	The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4987-96.	7.1	260
324	CD56 <sup>neg</sup> CD16 <sup>+</sup> NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. <i>Retrovirology</i> , 2013, 10, 158.	2.0	104

#	ARTICLE	IF	CITATIONS
325	Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunological Reviews, 2013, 254, 326-342.	6.0	334
326	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
327	Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet, The, 2013, 381, 2109-2117.	13.7	275
328	Short Communication: HIV+ Viremic Slow Progressors Maintain Low Regulatory T Cell Numbers in Rectal Mucosa but Exhibit High T Cell Activation. AIDS Research and Human Retroviruses, 2013, 29, 172-177.	1.1	13
329	Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology, 2013, 10, 106.	2.0	79
330	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. Journal of Infectious Diseases, 2013, 208, 1202-1211.	4.0	285
331	The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence. Journal of Infectious Diseases, 2013, 208, 1212-1220.	4.0	154
332	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. Journal of Infectious Diseases, 2013, 208, 1240-1249.	4.0	43
333	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	5.8	90
334	Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. Aids, 2013, 27, 2691-2696.	2.2	9
335	T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques. Journal of Virology, 2013, 87, 6073-6080.	3.4	6
336	Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. PLoS Pathogens, 2013, 9, e1003347.	4.7	244
337	Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. PLoS Pathogens, 2013, 9, e1003691.	4.7	94
338	Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration. Journal of Infectious Diseases, 2013, 207, 213-222.	4.0	183
339	Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. Journal of Infectious Diseases, 2013, 208, 50-56.	4.0	227
340	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathogens, 2013, 9, e1003174.	4.7	524
341	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. PLoS Pathogens, 2013, 9, e1003515.	4.7	109
342	AIDS Alters the Commensal Plasma Virome. Journal of Virology, 2013, 87, 10912-10915.	3.4	89

#	ARTICLE	IF	CITATIONS
343	Increase in 2â€™Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1436-1442.	4.0	151
344	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. <i>Blood</i> , 2013, 121, 4635-4646.	1.4	117
345	Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1221-1229.	6.3	152
346	Preclinical Evaluation of HIV Eradication Strategies in the Simian Immunodeficiency Virus-Infected Rhesus Macaque: A Pilot Study Testing Inhibition of Indoleamine 2,3-Dioxygenase. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 207-214.	1.1	16
347	Genetic interplay between<i>HLA-C</i>and<i>MIR148A</i>in HIV control and Crohn disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20705-20710.	7.1	109
348	Roadblocks to translational challenges on viral pathogenesis. <i>Nature Medicine</i> , 2013, 19, 30-34.	30.7	7
349	Association of HLA-DRB1â€™restricted CD4+ T cell responses with HIV immune control. <i>Nature Medicine</i> , 2013, 19, 930-933.	30.7	88
350	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. <i>Blood</i> , 2013, 121, 1124-1135.	1.4	347
351	Response: maraviroc intensification and microbial translocation. <i>Blood</i> , 2013, 122, 2283-2284.	1.4	5
352	Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. <i>Aids</i> , 2013, 27, 2255-2260.	2.2	44
353	The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. <i>Aids</i> , 2013, 27, 2101-2110.	2.2	18
354	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 149-163.	2.1	188
355	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. <i>Aids</i> , 2013, 27, 973-979.	2.2	315
356	Cortisol Patterns Are Associated with T Cell Activation in HIV. <i>PLoS ONE</i> , 2013, 8, e63429.	2.5	31
357	Higher CD27+CD8+ T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4+ T Cell Recovery in Treated HIV Infection. <i>PLoS ONE</i> , 2013, 8, e84091.	2.5	9
358	Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals In The Center For AIDS Research Network Of Integrated Clinical Systems. <i>Blood</i> , 2013, 122, 4331-4331.	1.4	1
359	Gag-Positive Reservoir Cells Are Susceptible to HIV-Specific Cytotoxic T Lymphocyte Mediated Clearance In Vitro and Can Be Detected In Vivo. <i>PLoS ONE</i> , 2013, 8, e71879.	2.5	51
360	Increased CD34<sup>+</sup>/KDR<sup>+</sup> cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects. <i>Antiviral Therapy</i> , 2012, 17, 557-563.	1.0	22



#	ARTICLE	IF	CITATIONS
361	CD28-Negative CD4+ and CD8+ T Cells in Antiretroviral Therapyâ€œNaive HIV-Infected Adults Enrolled in Adult Clinical Trials Group Studies. <i>Journal of Infectious Diseases</i> , 2012, 205, 1730-1738.	4.0	31
362	Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. <i>PLoS Genetics</i> , 2012, 8, e1002514.	3.5	66
363	Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough?. <i>Clinical Infectious Diseases</i> , 2012, 54, 733-735.	5.8	16
364	Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2012, 205, 1788-1796.	4.0	100
365	Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. <i>Aids</i> , 2012, 26, 1869-1878.	2.2	63
366	The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/ÅL in a Public Health Setting. <i>Clinical Infectious Diseases</i> , 2012, 55, 1690-1697.	5.8	28
367	HIV Infection Is Associated With Decreased Thrombin Generation. <i>Clinical Infectious Diseases</i> , 2012, 54, 1196-1203.	5.8	22
368	Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5998-6000.	3.2	56
369	Carotid Intimaâ€œMedia Thickness Progression in HIVâ€œInfected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. <i>Journal of the American Heart Association</i> , 2012, 1, .	3.7	87
370	Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 469-477.	1.1	62
371	Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2012, 205, S375-S382.	4.0	228
372	HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation. <i>Clinical Infectious Diseases</i> , 2012, 55, 126-136.	5.8	221
373	Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV?. <i>Clinical Infectious Diseases</i> , 2012, 54, 984-994.	5.8	197
374	Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. <i>Aids</i> , 2012, 26, 1967-1969.	2.2	31
375	A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 317-325.	2.1	36
376	Association of tenofovir exposure with kidney disease risk in HIV infection. <i>Aids</i> , 2012, 26, 867-875.	2.2	347
377	A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. <i>Aids</i> , 2012, 26, 805-814.	2.2	83
378	HIV and Aging. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S1-S18.	2.1	474



#	ARTICLE	IF	CITATIONS
379	The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. <i>Aids</i> , 2012, 26, 1115-1120.	2.2	70
380	Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. <i>Blood</i> , 2012, 119, 745-755.	1.4	38
381	Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. <i>Blood</i> , 2012, 119, 3469-3477.	1.4	36
382	HIV infection, lymphoid fibrosis, and disease. <i>Blood</i> , 2012, 120, 1753-1754.	1.4	7
383	Case 30-2012. <i>New England Journal of Medicine</i> , 2012, 367, 1246-1254.	27.0	2
384	Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease. <i>Cell Stem Cell</i> , 2012, 10, 137-147.	11.1	110
385	Epistatic interactions between Fc (GM) and FcÎ³R genes and the host control of human immunodeficiency virus replication. <i>Human Immunology</i> , 2012, 73, 263-266.	2.4	21
386	Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. <i>Human Molecular Genetics</i> , 2012, 21, 4334-4347.	2.9	61
387	Immunosenescence and HIV. <i>Current Opinion in Immunology</i> , 2012, 24, 501-506.	5.5	126
388	Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e39311.	2.5	17
389	Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e41021.	2.5	26
390	Differential Expression of CD96 Surface Molecule Represents CD8+ T Cells with Dissimilar Effector Function during HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e51696.	2.5	15
391	Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. <i>Science Translational Medicine</i> , 2012, 4, 132ra53.	12.4	555
392	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	22.7	485
393	Towards a cure for HIV. <i>Nature</i> , 2012, 487, 293-294.	27.8	23
394	Shock and kill. <i>Nature</i> , 2012, 487, 439-440.	27.8	525
395	Carotid Intima-Media Thickness Among Human Immunodeficiency Virus-Infected Patients Without Coronary Calcium. <i>American Journal of Cardiology</i> , 2012, 109, 742-747.	1.6	46
396	Lack of Evidence for mtDNA as a Biomarker of Innate Immune Activation in HIV Infection. <i>PLoS ONE</i> , 2012, 7, e50486.	2.5	14

#	ARTICLE	IF	CITATIONS
397	Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. <i>Blood</i> , 2011, 117, 3799-3808.	1.4	146
398	Breaking Free of Sample Size Dogma to Perform Innovative Translational Research. <i>Science Translational Medicine</i> , 2011, 03, 87ps24.	12.4	122
399	Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection. <i>Gastroenterology</i> , 2011, 141, 1220-1230.e3.	1.3	268
400	How to escape treatment. <i>Nature</i> , 2011, 477, 36-37.	27.8	15
401	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. <i>Blood</i> , 2011, 117, 5142-5151.	1.4	140
402	HIV Infection, Inflammation, Immunosenescence, and Aging. <i>Annual Review of Medicine</i> , 2011, 62, 141-155.	12.2	1,109
403	T cell activation predicts carotid artery stiffness among HIV-infected women. <i>Atherosclerosis</i> , 2011, 217, 207-213.	0.8	117
404	A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers. <i>PLoS ONE</i> , 2011, 6, e15924.	2.5	122
405	Retention in Care and Connection to Care among HIV-Infected Patients on Antiretroviral Therapy in Africa: Estimation via a Sampling-Based Approach. <i>PLoS ONE</i> , 2011, 6, e21797.	2.5	81
406	Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. <i>Aids</i> , 2011, 25, 2123-2131.	2.2	195
407	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. <i>Aids</i> , 2011, 25, 1813-1822.	2.2	140
408	N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. <i>Aids</i> , 2011, 25, 651-657.	2.2	29
409	HIV disease progression correlates with the generation of dysfunctional naive CD8low T cells. <i>Blood</i> , 2011, 117, 2189-2199.	1.4	30
410	Differential microRNA regulation of HLA-C expression and its association with HIV control. <i>Nature</i> , 2011, 472, 495-498.	27.8	328
411	Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. <i>Journal of Virological Methods</i> , 2011, 175, 261-265.	2.1	7
412	Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV. <i>Science Translational Medicine</i> , 2011, 3, 91ps30.	12.4	12
413	HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2011, 52, 681-687.	5.8	33
414	Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1474-1483.	4.0	308

#	ARTICLE	IF	CITATIONS
415	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790.	4.0	957
416	A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response. <i>Journal of Infectious Diseases</i> , 2011, 203, 960-968.	4.0	176
417	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	3.4	9
418	Increased Frequency of Regulatory T Cells Accompanies Increased Immune Activation in Rectal Mucosae of HIV-Positive Noncontrollers. <i>Journal of Virology</i> , 2011, 85, 11422-11434.	3.4	98
419	Association of Vitamin D Insufficiency with Carotid Intima-Media Thickness in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2011, 52, 941-944.	5.8	44
420	Viremia Copy-Years Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 53, 927-935.	5.8	122
421	Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. <i>Aids</i> , 2011, 25, 1289-1298.	2.2	130
422	Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection. <i>Journal of Virology</i> , 2011, 85, 6977-6985.	3.4	50
423	Reappraisal of the Relationship between the HIV-1-Protective Single-Nucleotide Polymorphism 35 Kilobases Upstream of the <i>HLA-C</i> Gene and Surface HLA-C Expression. <i>Journal of Virology</i> , 2011, 85, 3367-3374.	3.4	52
424	T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2011, 203, 452-463.	4.0	281
425	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	4.0	33
426	The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From <i>Pneumocystis jirovecii</i> Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation. <i>Clinical Infectious Diseases</i> , 2011, 53, 1008-1014.	5.8	9
427	Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. <i>Journal of Infectious Diseases</i> , 2011, 203, 1174-1181.	4.0	125
428	Human Endogenous Retrovirus K106 (HERV-K106) Was Infectious after the Emergence of Anatomically Modern Humans. <i>PLoS ONE</i> , 2011, 6, e20234.	2.5	46
429	Immune Activation, Cd4+ T Cell Counts, and Viremia Exhibit Oscillatory Patterns over Time in Patients with Highly Resistant HIV Infection. <i>PLoS ONE</i> , 2011, 6, e21190.	2.5	12
430	HIV RNA level in early infection is predicted by viral load in the transmission source. <i>Aids</i> , 2010, 24, 941-945.	2.2	65
431	Biomarkers in HIV disease. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 459-462.	3.8	9
432	HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. <i>Aids</i> , 2010, 24, 1095-1105.	2.2	127

#	ARTICLE	IF	CITATIONS
433	Spending More to Save More: Interventions to Promote Adherence. <i>Annals of Internal Medicine</i> , 2010, 152, 54.	3.9	26
434	Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. <i>Blood</i> , 2010, 115, e20-e32.	1.4	36
435	When to Start Antiretroviral Therapy. <i>Current HIV/AIDS Reports</i> , 2010, 7, 60-68.	3.1	28
436	Effects of thymic selection of the T-cell repertoire on HLA class II-associated control of HIV infection. <i>Nature</i> , 2010, 465, 350-354.	27.8	269
437	Can HIV be cured with stem cell therapy?. <i>Nature Biotechnology</i> , 2010, 28, 807-810.	17.5	25
438	Cytomegalovirus-Specific T Cells Persist at Very High Levels during Long-Term Antiretroviral Treatment of HIV Disease. <i>PLoS ONE</i> , 2010, 5, e8886.	2.5	176
439	Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. <i>PLoS ONE</i> , 2010, 5, e15510.	2.5	64
440	How Do HIV Elite Controllers Do What They Do?. <i>Clinical Infectious Diseases</i> , 2010, 51, 239-241.	5.8	43
441	Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T <sub>H</sub> 17 to Regulatory T Cells in HIV Disease. <i>Science Translational Medicine</i> , 2010, 2, 32ra36.	12.4	454
442	HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4 <sup>+</sup> T-Cell Responses. <i>Journal of Virology</i> , 2010, 84, 11020-11029.	3.4	102
443	Immunodominant HIV-Specific CD8 <sup>+</sup> T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. <i>Journal of Virology</i> , 2010, 84, 10354-10365.	3.4	61
444	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	5.8	187
445	Impact of HIV Infection on Diastolic Function and Left Ventricular Mass. <i>Circulation: Heart Failure</i> , 2010, 3, 132-139.	3.9	163
446	Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons. <i>Circulation</i> , 2010, 121, 651-658.	1.6	153
447	Treatment-Mediated Alterations in HIV Fitness Preserve CD4 <sup>+</sup> T Cell Counts but Have Minimal Effects on Viral Load. <i>PLoS Computational Biology</i> , 2010, 6, e1001012.	3.2	19
448	Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. <i>Aids</i> , 2010, 24, 1001-1005.	2.2	25
449	Initiation of antiretroviral therapy at higher nadir CD4 <sup>+</sup> T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. <i>Aids</i> , 2010, 24, 1897-1905.	2.2	65
450	A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5. <i>Journal of Virology</i> , 2010, 84, 10863-10876.	3.4	100

#	ARTICLE	IF	CITATIONS
451	Antiretroviral therapy and management of HIV infection. <i>Lancet</i> , The, 2010, 376, 49-62.	13.7	348
452	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. <i>Science</i> , 2010, 330, 1551-1557.	12.6	1,054
453	The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy. <i>PLoS ONE</i> , 2009, 4, e7196.	2.5	104
454	Characterization of Human Immunodeficiency Virus Type 1 Populations Containing CXCR4-Using Variants from Recently Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 795-802.	1.1	40
455	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1177-1185.	4.0	527
456	In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. <i>Journal of Virology</i> , 2009, 83, 2038-2043.	3.4	76
457	Incomplete Peripheral CD4 <sup>+</sup> Cell Count Restoration in HIV-infected Patients Receiving Long-term Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2009, 48, 787-794.	5.8	329
458	Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy. <i>Journal of Virology</i> , 2009, 83, 329-335.	3.4	191
459	HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. <i>Aids</i> , 2009, 23, 2143-2149.	2.2	99
460	Cross-Sectional Dating of Novel Haplotypes of HERV-K 113 and HERV-K 115 Indicate These Proviruses Originated in Africa before <i>Homo sapiens</i> . <i>Molecular Biology and Evolution</i> , 2009, 26, 2617-2626.	8.9	34
461	Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. <i>Aids</i> , 2009, 23, 1059-1067.	2.2	324
462	CD4 <sup>+</sup> T Cell Recovery with Antiretroviral Therapy: More Than the Sum of the Parts. <i>Clinical Infectious Diseases</i> , 2009, 48, 362-364.	5.8	23
463	Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 6782-6789.	3.4	252
464	Transcriptional Errors in Human Immunodeficiency Virus Type 1 Generate Targets for T-Cell Responses. <i>Vaccine Journal</i> , 2009, 16, 1369-1371.	3.1	14
465	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	5.8	55
466	HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. <i>Nature Genetics</i> , 2009, 41, 1290-1294.	21.4	265
467	Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. <i>Computational Statistics and Data Analysis</i> , 2009, 53, 766-775.	1.2	6
468	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	27.0	986

#	ARTICLE	IF	CITATIONS
469	Delaying a Treatment Switch in Antiretroviral-Treated HIV Type 1-Infected Patients with Detectable Drug-Resistant Viremia Does Not Have a Profound Effect on Immune Parameters: AIDS Clinical Trials Group Study A5115. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 135-139.	1.1	6
470	HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. <i>BMJ: British Medical Journal</i> , 2009, 338, a3172-a3172.	2.3	579
471	Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. <i>Aids</i> , 2009, 23, 1965-1970.	2.2	36
472	Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. <i>Aids</i> , 2009, 23, 2021-2027.	2.2	137
473	Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. <i>Blood</i> , 2009, 113, 3978-3989.	1.4	198
474	Reduced thymus activity and infection prematurely age the immune system. <i>Journal of Clinical Investigation</i> , 2009, 119, 2884-2887.	8.2	20
475	Human Herpesvirus Replication and Abnormal CD8+ T Cell Activation and Low CD4+ T Cell Counts in Antiretroviral-Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2009, 4, e5277.	2.5	18
476	Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2009, 17, 118-23.	2.9	131
477	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. <i>Nature Medicine</i> , 2008, 14, 413-420.	30.7	118
478	Raltegravir. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 117-118.	46.4	26
479	Relationship between T Cell Activation and CD4 <sup>+</sup> T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. <i>Journal of Infectious Diseases</i> , 2008, 197, 126-133.	4.0	579
480	Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 572-576.	2.1	20
481	HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control. <i>Journal of Virology</i> , 2008, 82, 5398-5407.	3.4	200
482	HIV-Induced Changes in T Cell Signaling Pathways. <i>Journal of Immunology</i> , 2008, 180, 6490-6500.	0.8	35
483	Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. <i>Aids</i> , 2008, 22, 825-833.	2.2	107
484	Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. <i>Aids</i> , 2008, 22, 2097-2106.	2.2	105
485	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 544-552.	2.1	52
486	Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels. <i>PLoS ONE</i> , 2008, 3, e2783.	2.5	174

#	ARTICLE	IF	CITATIONS
487	Clinical Implications of HIV Fitness and Virulence. , 2008, , 161-169.		0
488	Transmitted Minority Drug-Resistant HIV Variants: A New Epidemic?. PLoS Medicine, 2008, 5, e164.	8.4	10
489	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. Antiviral Therapy, 2008, 13, 369-374.	1.0	27
490	Comparison of an Interferon- $\gamma$ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 737-742.	5.6	185
491	Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. Journal of Virology, 2007, 81, 3240-3250.	3.4	68
492	History-adjusted Marginal Structural Models for Estimating Time-varying Effect Modification. American Journal of Epidemiology, 2007, 166, 985-993.	3.4	47
493	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of Epidemiology, 2007, 36, 294-301.	1.9	176
494	Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline—Reply. JAMA - Journal of the American Medical Association, 2007, 297, 805.	7.4	0
495	Interruption of Enfuvirtide in HIV-1 Infected Adults with Incomplete Viral Suppression on an Enfuvirtide-Based Regimen. Journal of Infectious Diseases, 2007, 195, 387-391.	4.0	41
496	Partial treatment interruptions. Current Opinion in HIV and AIDS, 2007, 2, 46-55.	3.8	3
497	A new approach for “deep salvage” trials in advanced HIV infection. Aids, 2007, 21, 1503-1506.	2.2	8
498	Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. Aids, 2007, 21, 2363-2365.	2.2	31
499	Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy. Immunity, 2007, 27, 406-416.	14.3	646
500	Individualized treatment rules: Generating candidate clinical trials. Statistics in Medicine, 2007, 26, 4578-4601.	1.6	17
501	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genetics, 2007, 39, 733-740.	21.4	691
502	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology, 2007, 8, 1324-1336.	14.5	152
503	Protease Inhibitors as Immunomodulatory Drugs for HIV Infection. Clinical Pharmacology and Therapeutics, 2007, 82, 248-250.	4.7	8
504	Loss of T cell responses following long-term cryopreservation. Journal of Immunological Methods, 2007, 326, 93-115.	1.4	88



#	ARTICLE	IF	CITATIONS
505	Adherence-resistance relationships to combination HIV antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2007, 4, 65-72.	3.1	156
506	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. <i>Antiviral Therapy</i> , 2007, 12, 531-541.	1.0	18
507	Immune-Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases?. <i>Journal of Infectious Diseases</i> , 2006, 194, 1632-1634.	4.0	16
508	Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses. <i>Journal of Virology</i> , 2006, 80, 6155-6164.	3.4	127
509	Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. <i>Lancet</i> , The, 2006, 367, 711-713.	13.7	22
510	The risk of treatment versus the risk of HIV replication. <i>Lancet</i> , The, 2006, 367, 1955-1956.	13.7	6
511	The independent effect of drug resistance on T cell activation in HIV infection. <i>Aids</i> , 2006, 20, 691-699.	2.2	35
512	Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 43, 60-64.	2.1	108
513	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. <i>Nature Medicine</i> , 2006, 12, 1365-1371.	30.7	3,107
514	CD8 T cell effector maturation in HIV-1-infected children. <i>Virology</i> , 2006, 347, 117-126.	2.4	11
515	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. <i>Aids</i> , 2006, 20, 2275-2283.	2.2	239
516	Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. <i>Aids</i> , 2006, 20, 223-231.	2.2	277
517	Antiretroviral treatment of HIV infected adults. <i>BMJ: British Medical Journal</i> , 2006, 332, 1489.	2.3	51
518	Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure. <i>Journal of Infectious Diseases</i> , 2006, 194, 1686-1696.	4.0	83
519	Predictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1498.	7.4	288
520	A Plea for Justice for Jailed Medical Workers. <i>Science</i> , 2006, 314, 924-925.	12.6	3
521	Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1-Infected Patients with Detectable Viremia. <i>Journal of Infectious Diseases</i> , 2006, 194, 926-930.	4.0	137
522	Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. <i>Clinical Infectious Diseases</i> , 2006, 43, 1329-1336.	5.8	87

#	ARTICLE	IF	CITATIONS
523	Continued Evolution in gp41 after Interruption of Enfuvirtide in Subjects with Advanced HIV Type 1 Disease. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1260-1266.	1.1	15
524	Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3384-3387.	3.9	9
525	A Randomized Pilot Study Comparing Combination Therapy plus Enfuvirtide versus a Treatment Interruption followed by Combination Therapy plus Enfuvirtide. <i>Antiviral Therapy</i> , 2006, 11, 315-319.	1.0	9
526	Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. <i>Aids</i> , 2005, 19, 989-990.	2.2	25
527	Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. <i>Aids</i> , 2005, 19, 1575-1585.	2.2	13
528	Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. <i>BMC Infectious Diseases</i> , 2005, 5, 98.	2.9	138
529	Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2005, 2, 6.	1.7	47
530	Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. <i>Journal of Virology</i> , 2005, 79, 14169-14178.	3.4	207
531	The Relationship between Nucleoside Analogue Treatment Duration, Insulin Resistance, and Fasting Arterialized Lactate Level in Patients with HIV Infection. <i>Clinical Infectious Diseases</i> , 2005, 41, 1335-1340.	5.8	41
532	Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug-Resistant HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1537-1544.	4.0	146
533	Multidrug-resistant, dual-tropic HIV-1 and rapid progression. <i>Lancet, The</i> , 2005, 365, 1924-1925.	13.7	4
534	Strong Cell-Mediated Immune Responses Are Associated with the Maintenance of Low-Level Viremia in Antiretroviral-Treated Individuals with Drug-Resistant Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 2004, 189, 312-321.	4.0	90
535	Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV Infection. <i>Circulation</i> , 2004, 109, 1603-1608.	1.6	552
536	Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy. <i>Journal of Immunology</i> , 2004, 173, 2184-2189.	0.8	66
537	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. <i>Journal of NeuroVirology</i> , 2004, 10, 44-51.	2.1	2
538	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. <i>Journal of NeuroVirology</i> , 2004, 10, 44-51.	2.1	20
539	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. <i>Journal of NeuroVirology</i> , 2004, 10, 44-51.	2.1	27
540	Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 696-699.	3.0	226

#	ARTICLE	IF	CITATIONS
541	Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. <i>Aids</i> , 2004, 18, 981-989.	2.2	101
542	Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. <i>Aids</i> , 2004, 18, 1965-1966.	2.2	63
543	Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. <i>Blood</i> , 2004, 104, 942-947.	1.4	688
544	The immune response to AIDS virus infection: good, bad, or both?. <i>Journal of Clinical Investigation</i> , 2004, 113, 808-810.	8.2	57
545	The immune response to AIDS virus infection: good, bad, or both?. <i>Journal of Clinical Investigation</i> , 2004, 113, 808-810.	8.2	39
546	Treating the latent reservoir of HIV. <i>Aids Reader</i> , 2004, 14, 485-6.	0.3	0
547	Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. <i>Journal of Immunological Methods</i> , 2003, 283, 141-153.	1.4	200
548	Treatment of antiretroviral-drug-resistant HIV-1 infection. <i>Lancet</i> , The, 2003, 362, 2002-2011.	13.7	181
549	T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus-Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2003, 187, 1534-1543.	4.0	786
550	Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options. <i>Journal of Infectious Diseases</i> , 2003, 188, 1001-1008.	4.0	33
551	Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. <i>Aids</i> , 2003, 17, 361-370.	2.2	80
552	High levels of adherence do not prevent accumulation of HIV drug resistance mutations. <i>Aids</i> , 2003, 17, 1925-1932.	2.2	200
553	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. <i>Aids</i> , 2003, 17, 1907-1915.	2.2	229
554	Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. <i>Aids</i> , 2003, 17, 53-63.	2.2	69
555	Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene. <i>Journal of Virology</i> , 2003, 77, 6743-6752.	3.4	46
556	Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection. <i>Annals of Internal Medicine</i> , 2003, 139, 258.	3.9	200
557	Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. <i>Aids</i> , 2003, 17, 917-919.	2.2	26
558	Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults. <i>Journal of Virology</i> , 2002, 76, 11104-11112.	3.4	151

#	ARTICLE	IF	CITATIONS
559	Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4+T Cell Decline in Human Immunodeficiency Virus-Infected Patients: Implications for Intermittent Therapeutic Strategies. <i>Journal of Infectious Diseases</i> , 2002, 186, 851-854.	4.0	50
560	A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy. <i>Molecular Therapy</i> , 2002, 5, 788-797.	8.2	275
561	CD4+T Cell Kinetics and Activation in Human Immunodeficiency Virus-Infected Patients Who Remain Viremic Despite Long-Term Treatment with Protease Inhibitor-Based Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 315-323.	4.0	103
562	Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients. <i>Journal of Infectious Diseases</i> , 2002, 185, 599-607.	4.0	171
563	Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. <i>Aids</i> , 2002, 16, F41-F47.	2.2	85
564	Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. <i>Aids</i> , 2002, 16, 201-207.	2.2	150
565	Supervised interruptions of antiretroviral therapy. <i>Aids</i> , 2002, 16, S157-S169.	2.2	14
566	Relationship of CD8+ T cell noncytotoxic anti-HIV response to CD4+ T cell number in untreated asymptomatic HIV-infected individuals. <i>Blood</i> , 2002, 99, 4225-4227.	1.4	33
567	Is average adherence to HIV antiretroviral therapy enough?. <i>Journal of General Internal Medicine</i> , 2002, 17, 812-813.	2.6	98
568	Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia. <i>New England Journal of Medicine</i> , 2001, 344, 472-480.	27.0	672
569	Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2733-2739.	3.2	319
570	Implications of antiretroviral resistance on viral fitness. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 23-28.	3.1	147
571	Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. <i>Aids</i> , 2001, 15, 179-184.	2.2	11
572	Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. <i>Aids</i> , 2001, 15, 117-119.	2.2	18
573	Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. <i>Aids</i> , 2001, 15, 1749-1756.	2.2	215
574	Cerebrospinal fluid response to structured treatment interruption after virological failure. <i>Aids</i> , 2001, 15, 1251-1259.	2.2	59
575	Hydroxyurea Does Not Enhance the Anti-HIV Activity of Low-Dose Tenofovir Disoproxil Fumarate. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 336-339.	2.1	7
576	Nonnucleoside Reverse Transcriptase Inhibitor Resistance. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26 Suppl 1, S25-S33.	2.1	82

#	ARTICLE	IF	CITATIONS
577	Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. <i>Nature Medicine</i> , 2001, 7, 73-79.	30.7	498
578	Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. <i>Nature Medicine</i> , 2001, 7, 712-718.	30.7	141
579	Primary and Recombinant HIV Type 1 Strains Resistant to Protease Inhibitors Are Pathogenic in Mature Human Lymphoid Tissues. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 517-523.	1.1	20
580	Durable HIV Treatment Benefit Despite Low-Level Viremia. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 224.	7.4	34
581	Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. <i>Aids</i> , 2000, 14, 2877-2887.	2.2	49
582	Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term Strategies. <i>Clinical Infectious Diseases</i> , 2000, 30, S177-S184.	5.8	106
583	Factors influencing T-cell turnover in HIV-1-seropositive patients. <i>Journal of Clinical Investigation</i> , 2000, 105, R1-R8.	8.2	207
584	HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. <i>Aids</i> , 1999, 13, F35-F43.	2.2	382
585	Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. <i>Aids</i> , 1999, 13, 1051-1061.	2.2	118
586	Antiretroviral Therapy for HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1343.	7.4	53
587	Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. <i>Aids</i> , 1998, 12, F97-F102.	2.2	90
588	Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( <i>R</i> )-1-hydroxy-2-phenyl-2-oxoethyl]-9H-fluoren-9-ylmethyl-3-thiouracil (FTC) in HIV-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2380-2384.	3.2	157
589	Genotypic-resistance assays and antiretroviral therapy. <i>Lancet</i> , The, 1997, 349, 1489-1490.	13.7	22
590	Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. <i>Lancet</i> , The, 1996, 348, 1547-1551.	13.7	74
591	Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. <i>Experimental Cell Research</i> , 1988, 174, 448-460.	2.6	59
592	LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. <i>Biomarkers in Medicine</i> , 0, , .	1.4	1